Načítá se...
Emerging treatment options for myelofibrosis: focus on pacritinib
Myelofibrosis (MF) is a myeloid malignancy associated with a heavy symptomatic burden that decreases quality of life and presents a risk for leukemic transformation. While there are limited curative treatments, the recent discovery of the Janus kinase/signal transducer and activator of transcription...
Uloženo v:
| Vydáno v: | Onco Targets Ther |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4863690/ https://ncbi.nlm.nih.gov/pubmed/27226728 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S93875 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|